RI
RTW INVESTMENTS, LP
RTW INVESTMENTS, LP · Investor
1Y performance ⓘ
+41%
AUM (13F)
$10.0B
# of Holdings
88
3Y performance ⓘ
+60%
vs S&P 500 ⓘ
−19%
Updated
Mar 31
RTW INVESTMENTS, LP's RTW INVESTMENTS, LP holds 88 U.S.-equity positions worth $10.0B (SEC 13F, Q1 2026). Top positions: Madrigal Pharmaceuticals, Inc. Common Stock 10.4%, Insmed, Inc. 7.9%, Protagonist Therapeutics, Inc 5.3%. 13F-replication return is +60% over 3 years (-19 pts vs the S&P 500) — a replicated, non-audited figure.
Holdings
| Stock | % of portfolio | Shares | Value | Latest activity | Avg buy price | Current price | Date |
|---|---|---|---|---|---|---|---|
| MDGL Madrigal Pharmaceuticals, Inc. Common Stock | 10.4% | 2.0M | $1.0B | — | $265.94 | $505.58 (+90%) | 2026-03-31 |
| INSM Insmed, Inc. | 7.9% | 4.8M | $792M | — | $92.32 | $115.23 (+25%) | 2026-03-31 |
| PTGX Protagonist Therapeutics, Inc | 5.3% | 5.1M | $533M | — | $25.55 | $140.09 (+448%) | 2026-03-31 |
| PTCT PTC Therapeutics, Inc. | 5.2% | 7.7M | $528M | — | $47.83 | $65.13 (+36%) | 2026-03-31 |
| ARGX Argenx Se | 5.2% | 709K | $518M | ▲ 5.3% (+36K) | $403.07 | $966.82 (+140%) | 2026-03-31 |
| CGON CG Oncology, Inc. Common stock | 4.7% | 7.0M | $473M | ▲ 247% (+5.0M) | $58.30 | $70.06 (+20%) | 2026-03-31 |
| CELC Celcuity Inc. Common Stock | 3.5% | 3.0M | $347M | ▲ 452% (+2.5M) | $111.53 | $78.75 (−29%) | 2026-03-31 |
| TNGX Tango Therapeutics, Inc. | 2.8% | 13.3M | $278M | ▲ 792% (+11.8M) | $19.68 | $24.81 (+26%) | 2026-03-31 |
| ERAS Erasca, Inc. Common Stock | 2.6% | 16.2M | $261M | ▲ 10917% (+16.0M) | $16.07 | $14.81 (−8%) | 2026-03-31 |
| NTRA Natera, Inc. Common Stock | 2.5% | 1.2M | $250M | ▼ 17% (−250K) | $55.36 | $415.50 (+651%) | 2026-03-31 |
| RDNT RadNet, Inc. Common Stock | 2.4% | 4.3M | $239M | ▲ 8.8% (+346K) | $55.90 | $68.93 (+23%) | 2026-03-31 |
| TARS Tarsus Pharmaceuticals, Inc. Common Stock | 2.3% | 3.3M | $235M | — | $20.13 | $78.93 (+292%) | 2026-03-31 |
| APGE Apogee Therapeutics, Inc. Common Stock | 2.3% | 2.8M | $234M | ▲ 2.6% (+70K) | $29.74 | — (+183%) | 2026-03-31 |
| SYRE Spyre Therapeutics, Inc. Common Stock | 2.1% | 4.2M | $210M | — | $23.64 | $90.56 (+283%) | 2026-03-31 |
| COGT Cogent Biosciences, Inc. Common Stock | 2.1% | 5.5M | $210M | ▼ 28% (−2.1M) | $25.86 | $32.31 (+25%) | 2026-03-31 |
| IRTC iRhythm Holdings, Inc. Common Stock | 2.0% | 1.7M | $197M | ▲ 41% (+487K) | $160.11 | $114.18 (−29%) | 2026-03-31 |
| STOK Stoke Therapeutics, Inc. Common Stock | 1.8% | 5.6M | $183M | ▲ 1.4% (+77K) | $11.04 | $26.20 (+137%) | 2026-03-31 |
| CYTK Cytokinetics Inc. | 1.8% | 2.7M | $179M | — | $36.56 | $66.02 (+81%) | 2026-03-31 |
| ACAD Acadia Pharmaceuticals Inc. | 1.6% | 7.1M | $159M | — | $19.67 | $20.02 (+2%) | 2026-03-31 |
| ESTA Establishment Labs Holdings Inc. | 1.5% | 2.7M | $151M | ▲ 2.6% (+67K) | $66.20 | $64.23 (−3%) | 2026-03-31 |
| APLSUSD Apellis Pharmaceuticals Inc | 1.5% | 3.7M | $148M | ▼ 52% (−4.0M) | $25.12 | — (+60%) | 2026-03-31 |
| IMCR Immunocore Hldgs Plc | 1.5% | 4.9M | $147M | — | $50.12 | $30.27 (−40%) | 2026-03-31 |
| RGEN Repligen Corp | 1.4% | 1.2M | $142M | ▲ 13% (+142K) | $158.44 | $189.74 (+20%) | 2026-03-31 |
| NBIX Neurocrine Biosciences Inc | 1.4% | 1.1M | $140M | — | $125.69 | $142.21 (+13%) | 2026-03-31 |
| GH Guardant Health, Inc. Common Stock | 1.4% | 1.5M | $137M | — | $47.50 | $177.00 (+273%) | 2026-03-31 |
| IMTX Immatics N.V. Ordinary Shares | 1.3% | 12.9M | $127M | ▲ 13% (+1.4M) | $9.80 | $8.78 (−10%) | 2026-03-31 |
| ZLAB Zai Lab Ltd | 1.2% | 6.6M | $124M | ▼ 5.5% (−385K) | $22.08 | $26.27 (+19%) | 2026-03-31 |
| BLTE Belite Bio Inc | 1.1% | 715K | $114M | — | $122.41 | $169.83 (+39%) | 2026-03-31 |
| ISRG Intuitive Surgical Inc. | 1.0% | 220K | $101M | ▲ 117% (+119K) | $430.41 | $408.78 (−5%) | 2026-03-31 |
| ORKA Oruka Therapeutics, Inc. Common Stock | 1.0% | 2.1M | $101M | — | $24.59 | $83.92 (+241%) | 2026-03-31 |
| GHRS GH Research PLC Ordinary Shares | 0.8% | 5.9M | $83M | — | $9.85 | $23.60 (+139%) | 2026-03-31 |
| XNCR Xencor, Inc. | 0.8% | 6.8M | $82M | — | $15.77 | $24.85 (+58%) | 2026-03-31 |
| URGN UroGen Pharma Ltd. Ordinary Shares | 0.8% | 4.5M | $82M | — | $13.67 | $40.98 (+200%) | 2026-03-31 |
| CNTA Centessa Pharmaceuticals Plc | 0.8% | 2.1M | $82M | ▲ 15% (+263K) | $19.82 | — (+100%) | 2026-03-31 |
| IMVT Immunovant, Inc. Common Stock | 0.8% | 3.2M | $79M | — | $25.31 | $34.30 (+36%) | 2026-03-31 |
| RARE Ultragenyx Pharmaceutical Inc. | 0.8% | 3.6M | $76M | ▲ 22% (+649K) | $33.97 | $15.11 (−56%) | 2026-03-31 |
| HNGE Hinge Health, Inc. | 0.7% | 1.9M | $74M | ▲ 446% (+1.6M) | $40.01 | $97.48 (+144%) | 2026-03-31 |
| CSTL Castle Biosciences, Inc. Common Stock | 0.7% | 2.8M | $68M | ▲ 30% (+643K) | $34.04 | $36.21 (+6%) | 2026-03-31 |
| RCKT Rocket Pharmaceuticals, Inc. Common Stock | 0.6% | 17.7M | $63M | — | $17.13 | $2.62 (−85%) | 2026-03-31 |
| TSHA Taysha Gene Therapies, Inc. Common Stock | 0.6% | 13.7M | $61M | ▼ 17% (−2.7M) | $2.22 | $4.90 (+121%) | 2026-03-31 |
| ALKS Alkermes Inc. plc | 0.6% | 1.7M | $59M | — | $27.26 | $40.85 (+50%) | 2026-03-31 |
| CMPS Compass Pathways Plc | 0.6% | 10.6M | $59M | ▲ 21% (+1.9M) | $3.73 | $12.19 (+226%) | 2026-03-31 |
| KOD Kodiak Sciences Inc Common Stock | 0.6% | 1.5M | $57M | — | $27.96 | $101.98 (+265%) | 2026-03-31 |
| REPL Replimune Group, Inc. | 0.6% | 7.4M | $56M | ▲ 3.0% (+217K) | $6.60 | $13.39 (+103%) | 2026-03-31 |
| CRNX Crinetics Pharmaceuticals, Inc. | 0.5% | 1.5M | $53M | ▲ 7.4% (+100K) | $38.75 | — (−6%) | 2026-03-31 |
| QURE uniQure N.V. | 0.4% | 2.6M | $42M | ▼ 30% (−1.1M) | $12.39 | $24.60 (+99%) | 2026-03-31 |
| WAY Waystar Holding Corp. Common Stock | 0.4% | 1.6M | $39M | NEW (+1.6M) | $24.11 | $26.50 (+10%) | 2026-03-31 |
| ARWR Arrowhead Research Corporation | 0.4% | 586K | $37M | — | $66.38 | $65.63 (−1%) | 2026-03-31 |
| OBIO Orchestra BioMed Holdings, Inc. Ordinary Shares | 0.3% | 8.3M | $35M | — | $14.12 | $6.25 (−56%) | 2026-03-31 |
| VSTM Verastem, Inc. | 0.3% | 6.6M | $35M | — | $6.82 | $8.08 (+18%) | 2026-03-31 |
Showing top 50 of 88 holdings by value.
FAQ ▾
What are RTW INVESTMENTS, LP's largest holdings?
As of the latest 13F: Madrigal Pharmaceuticals, Inc. Common Stock 10.4%, Insmed, Inc. 7.9%, Protagonist Therapeutics, Inc 5.3%, PTC Therapeutics, Inc. 5.2%, Argenx Se 5.2%.
How big is RTW INVESTMENTS, LP's 13F portfolio?
$10.0B across 88 disclosed U.S.-equity positions.
What is RTW INVESTMENTS, LP's 3-year performance?
+60% (13F-replication, price return), -19 pts vs the S&P 500. Not an audited fund return.
Where does this data come from?
U.S. SEC Form 13F-HR institutional holdings filings.
Sourced from SEC Form 13F-HR filings · Not investment advice ▾
Data as of 2026-03-31 · Methodology
13F-replication (price return, filing-date based) — not an audited fund return.
Published by WealthFile · Not investment advice.
Latest activity = change vs. the prior 13F. Avg buy price = est. entry over the trailing 3 years (gain = vs. latest price). Returns are 13F-replication, not audited fund returns. Sourced from SEC 13F filings.